Patents by Inventor Hideaki Kageji

Hideaki Kageji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES
    Publication number: 20230025510
    Abstract: The present invention provides a novel compound or a pharmaceutically acceptable salt thereof having an inhibitory action on an EGFR tyrosine kinase having an exon 20 insertion mutation and/or a HER2 tyrosine kinase having an exon 20 insertion mutation, a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, R4, R5 and R6 in the Formula (I) are each as defined in the description.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 26, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kenichi Yoshida, Kosuke Takeuchi, Hidekazu Inoue, Hideaki Kageji, Takayuki Momose, Keisuke Yoshida, Takeshi Jimbo, Akiko Egami
  • PYRIDINE COMPOUND
    Publication number: 20210163464
    Abstract: The present invention relates to a compound having RET kinase inhibiting action or a pharmaceutically acceptable salt thereof, useful in the treatment of diseases such as cancer. In particular a compound represented by the following general formula (I) as defined herein: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 24, 2020
    Publication date: June 3, 2021
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Hiroaki Inagaki, Yoshihiro Shibata, Hidenori Namiki, Hideaki Kageji, Kiyoshi Nakayama, Yasuyuki Kaneta
  • Pyridine compound
    Patent number: 10851092
    Abstract: The present invention relates to a compound having RET kinase inhibiting action or a pharmaceutically acceptable salt thereof, useful in the treatment of diseases such as cancer. In particular a compound represented by the following general formula (I) as defined herein: (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 1, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hiroaki Inagaki, Yoshihiro Shibata, Hidenori Namiki, Hideaki Kageji, Kiyoshi Nakayama, Yasuyuki Kaneta
  • PYRIDINE COMPOUND
    Publication number: 20200039974
    Abstract: The present invention relates to a compound having RET kinase inhibiting action or a pharmaceutically acceptable salt thereof, useful in the treatment of diseases such as cancer. In particular a compound represented by the following general formula (I) as defined herein: (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 28, 2017
    Publication date: February 6, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Hiroaki Inagaki, Yoshihiro Shibata, Hidenori Namiki, Hideaki Kageji, Kiyoshi Nakayama, Yasuyuki Kaneta